Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNA7I1
|
|||
| Drug Name |
OPT-302
|
|||
| Indication | Diabetic macular edema [ICD-11: 9B71.02] | Phase 2 | [1] | |
| Company |
Opthea
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor C (VEGFC) | Target Info | Inhibitor | [2] |
| Vascular endothelial growth factor D (VEGFD) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| TNF signaling pathway | ||||
| Pathways in cancer | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Pathway Interaction Database | Alpha9 beta1 integrin signaling events | |||
| VEGF and VEGFR signaling network | ||||
| VEGFR3 signaling in lymphatic endothelium | ||||
| Reactome | Platelet degranulation | |||
| VEGF ligand-receptor interactions | ||||
| VEGF binds to VEGFR leading to receptor dimerization | ||||
| WikiPathways | Focal Adhesion | |||
| Signaling by VEGF | ||||
| Heart Development | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03345082) A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Opthea. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.